Edgar Filing: ADVENTRX PHARMACEUTICALS INC - Form 8-K

ADVENTRX PHARMACEUTICALS INC Form 8-K November 07, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

November 3, 2008

ADVENTRX Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-32157	84-1318182
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
6725 Mesa Ridge Road, Suite 100, San Diego, California		92121
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including area of	code:	858-552-0866
	Not Applicable	
Former name or	former address, if changed since	last report
Check the appropriate box below if the Form 8-K filing is i the following provisions:	ntended to simultaneously satisfy	the filing obligation of the registrant under any of
[] Written communications pursuant to Rule 425 under th [] Soliciting material pursuant to Rule 14a-12 under the E [] Pre-commencement communications pursuant to Rule [] Pre-commencement communications pursuant to Rule	exchange Act (17 CFR 240.14a-1 14d-2(b) under the Exchange Act	2) t (17 CFR 240.14d-2(b))

Edgar Filing: ADVENTRX PHARMACEUTICALS INC - Form 8-K

Top of the Form

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 3, 2008, the Board of Directors (the "Board") of ADVENTRX Pharmaceuticals, Inc. (the "Company") appointed Mark N.K. Bagnall, currently the Company's Executive Vice President and Chief Financial Officer and a member of the Board, to additionally serve as the Company's principal executive officer on an interim basis, effective immediately. The Company has informally begun a search for a new Chief Executive Officer.

Mr. Bagnall, age 51, has served as the Company's Executive Vice President and Chief Financial Officer since April 3, 2008. He has served as a member of the Board since February 2004. Prior to his appointment as an officer of the Company, Mr. Bagnall served on the audit committee, the compensation committee and the nominating and governance committee of the Board, and as chair of the audit committee. Mr. Bagnall has over 20 years of experience in the biotechnology industry. From June 2000 to June 2007, he served as senior vice president and chief finance and operations officer of Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders. In the 12 years prior to joining Metabolex, Inc., Mr. Bagnall held the top financial position at four life science companies: Metrika, Inc., a privately held diagnostics company, Progenitor, Inc., Somatix Therapy Corporation, and Hana Biologics, Inc. Mr. Bagnall is a director of two publicly held biotechnology companies, VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, and Forticell Bioscience, Inc. (formerly Ortec International, Inc.), a biotechnology company focusing on advanced regenerative medicine and stem cell therapy. Mr. Bagnall received his B.S. in Business Administration from the University of California at Berkeley, Haas School of Business, and is a Certified Public Accountant.

The terms of Mr. Bagnall's employment with the Company were disclosed previously in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on April 7, 2008, and his offer letter was filed as an exhibit to the Company's Form 10-Q for the quarter ended June 30, 2008 on August 11, 2008.

Edgar Filing: ADVENTRX PHARMACEUTICALS INC - Form 8-K

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ADVENTRX Pharmaceuticals, Inc.

November 7, 2008 By: /s/ Patrick L. Keran

Name: Patrick L. Keran Title: Vice President, Legal